<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196154</url>
  </required_header>
  <id_info>
    <org_study_id>NMRR-17-122-33927</org_study_id>
    <nct_id>NCT03196154</nct_id>
  </id_info>
  <brief_title>Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics</brief_title>
  <acronym>InsuReB</acronym>
  <official_title>Cross-Sectional Study on Association Between the Estimation of Insulin Resistance and Beta Cell Function Through Homeostasis Model Assessment With HbA1C Among Oral Anti-Diabetics Treatment Non-Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Centre, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Centre, Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progression of T2DM is widely accepted to be contributed by two main components: beta cell
      function deterioration where insulin secretion is impaired and insulin resistance where
      insulin physiological response is reduced. Insulin resistance and beta cell function will be
      estimated through a mathematical model, homeostasis model assessment. Fasting insulin and
      C-peptide will be measured using liquid chromatography tandem mass spectrometry. Insulin
      resistance and beta cell function is then compared with the glycaemic control, HbA1C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective

      â€¢ To investigate the association between the estimation of insulin resistance and beta cell
      function through homeostasis model assessment with HbA1C among oral anti-diabetics treatment
      non-responder.

      Secondary Objectives

        -  To compare the insulin resistance and beta cell function between the OAD treatment
           responders (negative control) and non-responders

        -  To investigate the relationship between plasma level of metformin and gliclazide with
           the estimation of beta cell function and insulin resistance

        -  To identify the proportion of patients with high insulin resistance and proportion of
           patients with low beta cell function

        -  To identify difference in insulin resistance and beta cell function of different ethnic
           groups in Sarawak

        -  To compare insulin resistance with cardiovascular disease risk using Framingham Risk
           Score and ASCVD risk estimation
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA estimation of insulin resistance and beta cell function</measure>
    <time_frame>1 day</time_frame>
    <description>Insulin resistance and beta cell function is estimated through homeostasis model assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>1 day</time_frame>
    <description>Glycaemic control of subjects assessed through HbA1C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>1 day</time_frame>
    <description>Assessed using Malaysian Medication Adherence Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma metformin level</measure>
    <time_frame>1 day</time_frame>
    <description>Measured using LCMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma gliclazide level</measure>
    <time_frame>1 day</time_frame>
    <description>Measured using LCMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk estimation</measure>
    <time_frame>1 day</time_frame>
    <description>Framingham risk score and ASCVD risk estimation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">255</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <description>Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Gliclazide</arm_group_label>
    <description>Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fasting insulin level</intervention_name>
    <description>Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformin + Gliclazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasma drug level</intervention_name>
    <description>Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformin + Gliclazide</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All T2DM patients under Sarawak General Hospital, Sarawak Heart Centre, Tanah Puteh Health
        Clinic, Jalan Masjid Health Clinic and Petra Jaya Health Clinic follow up during the period
        3 July 2017 until 30 March 2018
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously diagnosed to have T2DM, currently treated with oral anti-diabetics agents
             (either on maximum dose of Metformin only or with maximum dose of Gliclazide) for at
             least 3 months with no change in medications and dosage during the period of 3 months

        Exclusion Criteria:

          -  Patient that is on exogenous insulin, is on hormone replacement therapy or any
             steroids medications, with renal impairment with creatinine clearance less than
             30ml/min and unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aylwin Ming Wee Lim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Centre, Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Centre, Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Research Centre, Malaysia</investigator_affiliation>
    <investigator_full_name>Aylwin Lim Ming Wee</investigator_full_name>
    <investigator_title>Research Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Homeostasis Model Assessment</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Beta Cell Function</keyword>
  <keyword>Liquid Chromatography Tandem Mass Spectrometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

